Your browser doesn't support javascript.
loading
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC.
Lara, Matthew S; Gubens, Matthew A; Bacaltos, Bianca; Daran, Lea; Lim, Steffany L; Li, Tianhong; Gandara, David R; Bivona, Trever G; Riess, Jonathan W; Blakely, Collin M.
Afiliación
  • Lara MS; Division of Hematology/Oncology, Department of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California.
  • Gubens MA; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, California.
  • Bacaltos B; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, California.
  • Daran L; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, California.
  • Lim SL; Division of Hematology/Oncology, Department of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California.
  • Li T; Division of Hematology/Oncology, Department of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California.
  • Gandara DR; Division of Hematology/Oncology, Department of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California.
  • Bivona TG; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, California.
  • Riess JW; Division of Hematology/Oncology, Department of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California.
  • Blakely CM; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, California.
JTO Clin Res Rep ; 3(12): 100436, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36545322

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: JTO Clin Res Rep Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: JTO Clin Res Rep Año: 2022 Tipo del documento: Article